Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dexcom (DXCM) EPS (Basic) (2016 - 2026)

Dexcom has reported EPS (Basic) over the past 17 years, most recently at $0.52 for Q1 2026.

  • Quarterly EPS (Basic) rose 92.59% to $0.52 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.4 through Mar 2026, up 77.78% year-over-year, with the annual reading at $2.14 for FY2025, 46.58% up from the prior year.
  • EPS (Basic) was $0.52 for Q1 2026 at Dexcom, down from $0.69 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.73 in Q3 2025 and troughed at $0.13 in Q2 2022.
  • The 5-year median for EPS (Basic) is $0.34 (2024), against an average of $0.38.
  • The largest YoY upside for EPS (Basic) was 2500.0% in 2022 against a maximum downside of 57.63% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at $0.24 in 2022, then surged by 175.0% to $0.66 in 2023, then tumbled by 42.42% to $0.38 in 2024, then skyrocketed by 81.58% to $0.69 in 2025, then dropped by 24.64% to $0.52 in 2026.
  • Per Business Quant, the three most recent readings for DXCM's EPS (Basic) are $0.52 (Q1 2026), $0.69 (Q4 2025), and $0.73 (Q3 2025).